Podcast
Patients with hypertension at risk for cardiovascular events have done better with an ACE inhibitor-calcium channel blocker combination than with the ACE inhibitor plus hydrochlorothiazide. The ACCOMPLISH investigators have now reported on their analysis of progression-of-nephropathy outcomes in their trial. We interview the first author of the analysis, Dr. George Bakris of the University of Chicago’s Pritzker School of Medicine.